Discussions

The tumor extracellular matrix with sdAb (single domain antibody) represents a cutting-edge area of cancer research. As scientists strive to understand the complex interactions within tumor microenvironments, the focus on the extracellular matrix, a critical component in tumor development and progression, becomes essential. Incorporating sdAb technology offers promising pathways for targeted therapy, as these small, stable antibodies can penetrate the dense matrix more effectively. This approach could potentially enhance the delivery of therapeutic agents, offering a more precise and effective treatment for patients.